NextCure, Inc. (NASDAQ:NXTC) Short Interest Down 32.1% in November

NextCure, Inc. (NASDAQ:NXTC) was the target of a significant drop in short interest in November. As of November 15th, there was short interest totalling 44,900 shares, a drop of 32.1% from the October 31st total of 66,100 shares. Currently, 0.2% of the shares of the stock are sold short. Based on an average daily volume of 43,000 shares, the days-to-cover ratio is currently 1.0 days.

Institutional Investors Weigh In On NextCure

A number of institutional investors have recently made changes to their positions in NXTC. Vanguard Group Inc. raised its position in NextCure by 9.3% in the 1st quarter. Vanguard Group Inc. now owns 987,324 shares of the company’s stock worth $2,202,000 after purchasing an additional 83,700 shares during the period. Logos Global Management LP increased its holdings in shares of NextCure by 29.9% in the second quarter. Logos Global Management LP now owns 2,500,000 shares of the company’s stock worth $3,975,000 after buying an additional 575,000 shares during the period. Armistice Capital LLC purchased a new position in shares of NextCure in the second quarter worth about $57,000. Affinity Asset Advisors LLC lifted its stake in shares of NextCure by 24.2% in the 2nd quarter. Affinity Asset Advisors LLC now owns 1,687,955 shares of the company’s stock valued at $2,684,000 after acquiring an additional 328,918 shares during the last quarter. Finally, Renaissance Technologies LLC boosted its holdings in NextCure by 15.4% during the 2nd quarter. Renaissance Technologies LLC now owns 462,144 shares of the company’s stock valued at $735,000 after acquiring an additional 61,744 shares during the period. Hedge funds and other institutional investors own 42.65% of the company’s stock.

Wall Street Analyst Weigh In

Separately, HC Wainwright decreased their price target on shares of NextCure from $8.00 to $4.00 and set a “buy” rating on the stock in a report on Monday, November 11th.

NextCure Price Performance

NXTC stock remained flat at $1.17 during mid-day trading on Friday. The company’s stock had a trading volume of 12,594 shares, compared to its average volume of 65,145. The firm’s 50 day simple moving average is $1.34 and its two-hundred day simple moving average is $1.47. NextCure has a 52-week low of $1.03 and a 52-week high of $2.57. The company has a market cap of $32.77 million, a PE ratio of -0.56 and a beta of 0.80.

NextCure Company Profile

NextCure, Inc, a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells.